Oncothyreon reports another tecemotide failure
This article was originally published in Scrip
Oncothyreon's cancer vaccine tecemotide missed another endpoint – this time in a Phase I/II study of Japanese patients with non-small cell lung cancer (NSCLC). The drug has already stalled in development once and the implications for the program are still unclear.
You may also be interested in...
The biotech already was looking to move into solid tumors, particularly breast cancer, with its antibody-drug conjugates, but now will take over a promising oral candidate in pivotal studies in HER2-positive breast cancer.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.